EirGenix`s Breast Cancer Biosimilar Receives Marketing Authorization by EC
22 Nov 2023 //
PR NEWSWIRE
EirGenix`s Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1
02 May 2023 //
PR NEWSWIRE
Sandoz submits BLA for proposed biosimilar trastuzumab to US FDA
22 Dec 2021 //
PHARMABIZ
Positive Phase III Clinical Results for EirGenix`s Proposed Trastuzumab
24 Mar 2021 //
PRNEWSWIRE
Shorla nabs $8.3M to bring improved cancer meds to the U.S.
02 Jun 2020 //
FIERCE BIOTECH